Artelo Biosciences Announces Publication of Peer-Reviewed Article Highlighting FABP7 as a Promising Novel Target in Cancer Therapy

Core Insights - Artelo Biosciences, Inc. has published an article in Drug Discovery Today discussing the role of fatty acid binding protein 7 (FABP7) in various cancers and its potential as a target for cancer treatment [1][2] - FABP7 is upregulated in several cancers, including breast, brain, and kidney cancers, and is associated with poor patient prognosis [2] - Genetic and pharmacological inhibition of FABP7 has shown to reduce tumor cell growth, migration, and invasion, while improving survival rates in brain cancer models [2] Company Developments - Artelo is advancing research on FABP inhibition, focusing on selective and pan-FABP inhibitors to provide new therapeutic options for cancer and other serious conditions [3] - The lead compound, ART26.12, is a selective inhibitor of FABP5, showing positive preclinical results in cancer and chemotherapy-induced peripheral neuropathy (CIPN) [3][5] - The company plans to file an investigational new drug (IND) application with the FDA for ART26.12 in CIPN during Q2 2024, addressing a significant unmet need as approximately 40% of cancer patients undergoing certain chemotherapies develop neuropathic pain [3][5] Research Focus - Artelo's research emphasizes the therapeutic potential of its extensive library of small molecule FABP inhibitors for treating various conditions, including cancers, pain, and anxiety disorders [5][6] - The company is dedicated to developing proprietary therapeutics that modulate lipid-signaling pathways to address significant unmet medical needs [6]